Food and Drug Administration (FDA) Office of Clinical Pharmacology (OCP) Multi-phase/Multi- site Clinical Studies and Laboratory Support Indefinite Delivery-Indefinite Quantity (IDIQ) Type Contract
This federal contract opportunity has been awarded to on September 15, 2025.
Award Information
This solicitation resulted in an award to for approximately $50,000,000 on September 15, 2025. Similar contracts are typically issued by HEALTH AND HUMAN SERVICES, DEPARTMENT OF under 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
- Award Number
- 75F40125D00003
- Award Amount
- $50,000,000
- Award Date
- September 15, 2025
Key Takeaways
- No response deadline specified - contact the agency for details
- Set-aside for Small Business businesses
- Work to be performed in Beltsville, MD
- Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Contract Details
- Notice ID
- 75F40124R00064
- Opportunity Type
- Award Notice
- Sub-Agency
- FOOD AND DRUG ADMINISTRATION
- Office
- FDA OFFICE OF ACQ GRANT SVCS
- Posted Date
- Tuesday, September 16, 2025
- Response Deadline
- Not specified
- PSC Code
- AJ12
- Set-Aside
- Small Business
- Place of Performance
- Beltsville, MD, 20705
- Status
- Active
Description
This is a commercial services Food and Drug Administration (FDA) open market single-award Indefinite Delivery-Indefinite Quantity (IDIQ) type contract set aside 100% for small business. The scope of activities FDA may require of the contractor shall include the capability to conduct multiple Phase I clinical trials within a year and at times in parallel, and the provision of a full range of services to support the clinical trials and reporting of the results. The Authorized Task Order (TO) type under this IDIQ contract is Firm-Fixed-Price (FFP).
Why This Opportunity Matters
HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking responses for research and development in biotechnology (except nanobiotechnology) with a set-aside for Small Business businesses in Beltsville, MD. This set-aside designation means eligible businesses face reduced competition from larger firms.
Similar Opportunities
AJ11-VA Depleted Uranium Program PO 512C50314
Q-RNAscope In-House Assay
Low-cost, Connected, Digital Lateral Flow Platform to Detect Influenza A, Influenza B, and SARS-Cov -2 for use in Over-the-Counter (OTC) Settings
A-High Throughput Transcriptomics (HTTr)
human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
